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Nonalcoholic fatty liver disease (NAFLD) is a major public health problem and the most common form of chronic liver disease, 
affecting 25% of the global population. Although NAFLD is closely linked with obesity, insulin resistance, and type 2 diabetes 
mellitus, knowledge on its pathogenesis remains incomplete. Emerging data have underscored the importance of Rho-kinase 
(Rho-associated coiled-coil-containing kinase [ROCK]) action in the maintenance of normal hepatic lipid homeostasis. In par-
ticular, pharmacological blockade of ROCK in hepatocytes or hepatic stellate cells prevents the progression of liver diseases such 
as NAFLD and fibrosis. Moreover, mice lacking hepatic ROCK1 are protected against obesity-induced fatty liver diseases by sup-
pressing hepatic de novo lipogenesis. Here we review the roles of ROCK as an indispensable regulator of obesity-induced fatty liv-
er disease and highlight the key cellular pathway governing hepatic lipid accumulation, with focus on de novo lipogenesis and its 
impact on therapeutic potential. Consequently, a comprehensive understanding of the metabolic milieu linking to liver dysfunc-
tion triggered by ROCK activation may help identify new targets for treating fatty liver diseases such as NAFLD.
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INTRODUCTION
During the 20th century, dramatic changes in lifestyle and eat-
ing habits led to a remarkable increase in obesity, which is a 
major risk factor for the development of nonalcoholic fatty liv-
er disease (NAFLD) [1,2]. NAFLD, known as the hepatic man-
ifestation of the metabolic syndrome, is the most common 
form of chronic liver disease. This condition is closely associat-
ed with insulin resistance, type 2 diabetes mellitus (T2DM), 
and obesity [3]. NAFLD is an umbrella term covering a broad 
spectrum of liver diseases characterized by different grades of 
severity in fat accumulation, inflammation, injury, and fibrosis 
[4]. The pathological manifestation of NAFLD ranges from 
simple steatosis or nonalcoholic fatty liver (NAFL) to nonalco-
holic steatohepatitis (NASH) and fibrosis/cirrhosis that can ul-
timately lead to hepatocellular carcinoma and liver failure 
[1,2,4]. NAFL or fatty liver refers to simple steatosis character-
ized by storage of excess macrovesicular fat in more than 5% of 
hepatocytes. NASH is considered the most severe disease 
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pericellular fibrosis, and ultimately can progress to cirrhosis 
and hepatocellular carcinoma [5]. 
The worldwide prevalence of NAFLD is 6% to 35% (median 
20%) [6], whereas the estimated prevalence in the United 
States varies from 18% in the overall population to 28% in 
overweight individuals [7]. Individuals with NAFLD are gen-
erally obese and often present other pathophysiologic features 
of the metabolic syndrome, including insulin resistance, hy-
pertension, dyslipidemia, and diabetes [8,9]. In fact, NAFLD 
prevalence amongst individuals with T2DM is 55.5% and 
37.3% for NASH [10]. Thus, identifying new insights into the 
biological foundations of obesity-related fatty liver is highly 
crucial given the substantial rise in NAFLD prevalence world-
wide. In this review, we discuss the emerging roles of Rho-ki-
nase in the development of fatty liver disease and the conse-
quences on systemic glucose homeostasis, with a particular fo-
cus on a molecular link with hepatic de novo lipogenesis 
(DNL). 
PATHOLOGY OF NONALCOHOLIC FATTY 
LIVER DISEASES
The liver is an important metabolic organ that is essential for 
maintaining whole-body glucose and lipid homeostasis [1]. Im-
paired liver functions lead to insulin resistance causing T2DM 
and is often found in obesity-associated metabolic diseases 
such as NAFLD [1,11]. The pathophysiological mechanism(s) 
underlying NAFLD onset and progression appears to be a 
‘multiple-hit’ process that includes insulin resistance, hor-
mones secreted from the adipose tissue, nutritional factors, gut 
microbiota as well as genetic and epigenetic factors [12]. Ini-
tially, an increase in liver fat accumulation through a disrup-
tion of the homeostatic balance between triglyceride synthesis 
and clearance is detected. However, hepatic lipogenic pathways 
and concomitant inflammation are activated when obesity de-
velops [12]. Specifically, pro-inflammatory cytokines secreted 
by adipose tissue is involved in the pathological process of ec-
topic fat accumulation within the hepatocyte and overall ste-
atosis [13]. This development implies that the liver is not nec-
essarily responsible for the initial development of metabolic 
inflammation but, with the gradual progression of obesity, is 
an important contributor to perpetuating this overall state of 
inflammation. Additionally, mitochondrial dysfunction in the 
liver is crucial in NAFLD development in metabolic disorders 
such as metabolic syndrome, obesity, and T2DM [14,15]. The 
delicate metabolic homeostasis between lipid accumulation 
and fuel utilization in liver cells is regulated by mitochondrial 
activity, including β-oxidation of free fatty acids, electron 
transfer and adenosine triphosphate production, as well as re-
active oxygen species (ROS). Any imbalance between pro- and 
anti-oxidant activities leads to a decrease in β-oxidation and 
an increase in ROS production [14], which could ultimately 
contribute to NAFLD’s pathogenesis. 
Several types of the cells were found in the liver, including 
hepatic parenchymal cells, sinusoidal endothelial cells, hepatic 
stellate cells (HSCs), Kupffer cells, and dendritic cells [16]. 
HSCs comprise approximately 10% of all liver cells. These cells 
are typically found in the space of Disse, lying between liver si-
nusoidal endothelial cells and hepatocytes [17]. In a non-path-
ological state, HSCs are dormant, displaying a quiescent, non-
proliferative phenotype (qHSCs). This cell stores vitamin A, 
cholesteryl esters and triglycerides in lipid vacuoles in the cyto-
sol [18]. HSCs, in physiological conditions, regulate extracellu-
lar matrix (ECM) homeostasis through the release of ECM 
proteins, degrading enzymes (matrix metalloproteinases), and 
their tissue inhibitors. qHSCs are also known to produce a 
range of growth factors and other metabolic mediators such as 
the hepatocyte growth factor and vascular endothelial growth 
factor [19]. Following liver injury, HSCs are activated into myo-
fibroblasts that drive expressing fibrogenic genes, including 
collagen type 1, α-smooth muscle actin, and the tissue inhibi-
tor of metalloproteinase. They proliferate and migrate to the 
liver injury site, where ECM secretion is stimulated [20]. Sever-
al studies have shown that fibrosis can be reversed upon the in-
jury’s removal, specifically, myofibroblasts will undergo apop-
tosis and inactivation, promoting fibrosis regression [21,22].
Kupffer cells are liver resident macrophages located within 
the lumen of the sinusoids and are adherent to the endothelial 
cells composing the blood vessel walls [18]. These cells play a 
key role in preventing undesired immune response under nor-
mal conditions, whereas they are activated under the patho-
physiological conditions such as NAFLD. Activated Kupffer 
cells induce numerous inflammatory chemokines and cyto-
kines secretion, resulting in detrimental effects on hepatic 
function, inflammation, and insulin resistance [18,23]. In fact, 
chemical-mediated ablation of Kupffer cells protects hepatic 
insulin resistance and hepatic steatosis in response to a high-
fat diet (HFD) [24,25], highlighting the vital role for Kupffer 
cells in the progression of hepatic lipid accumulation. Notably, 
Kupffer cells also induce HSCs from a quiescent state to an ac-
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tivated state, leading to the production of collages and initia-
tion of liver fibrogenesis [26]. The regulatory mechanisms un-
derlying this phenomenon remain to be elucidated.
Rho-KINASE INHIBITOR AMELIORATES 
NONALCOHOLIC FATTY LIVER DISEASES
Rho-associated coiled-coil-containing kinase (ROCK) is a ser-
ine/threonine protein kinase identified as a guanosine triphos-
phate (GTP)-Rho-binding protein [27]. Two isoforms of 
ROCK, ROCK1 (also known as ROKβ) [28,29] and ROCK2 
(also known as ROKα) [28,30] were identified. ROCK has a 
kinase domain at its N-terminal domain, a coiled-coil domain 
in its middle portion, and a putative pleckstrin-homology do-
main at its C-terminal domain split by the insertion of a Cys-
rich region. The Rho binding domain of ROCK is in the C-ter-
minal portion of the coiled-coil domain [27]. ROCK activity 
increases when bound with (Rho-GTP) Rho-GTP through a 
Rho-binding domain [27]. The amino acid sequences of the 
two ROCK isoforms have 65% overall identity, with their ki-
nase domains exhibiting 92% identity [27].
The initial study of the ROCK inhibitor led by the Narumiya 
group demonstrated that treating a hypertensive animal with a 
high dose of the ROCK inhibitor (Y27632, 100 mg/kg/day for 
5 months) results in decreased blood pressure [31]. These data 
suggest the ROCK inhibitor is a potential therapeutic target for 
many diseases resulting from abnormally high smooth muscle 
contraction. Since the introduction of this work, numerous 
studies have consistently revealed that ROCK inhibition is 
beneficial for multiple cardiovascular-related illnesses [32-34]. 
Beyond these investigations, a pharmacotherapy with the 
ROCK inhibitor has also been found to be effective in treating 
liver diseases, including NAFLD, NASH, and fibrosis as shown 
in Table 1 [35-53]. Data supporting a role of ROCK on liver 
diseases include the fact that a ROCK chemical inhibitor ame-
liorated hepatic steatosis and fibrosis in rats fed a choline-defi-
cient/L-amino acid-defined (CDAA) diet and choline-defi-
cient diet [35-37]. These findings are also accompanied by de-
creased alanine aminotransferase (ALT)/aspartate amino-
transferase (AST) and serum lipids levels [37]. The cellular 
mechanism(s) underlying this phenomenon could include in-
volvement of the inactivation of HSCs [35-37], which have a 
crucial role in the development of hepatic fibrosis [54]. In sup-
port of this, the experimental evidence has demonstrated that 
selective delivery of the ROCK inhibitor to HSCs reduces 
chronic carbon tetrachloride (CCl4)-induced liver fibrosis or 
cirrhosis by inhibiting activated HSCs in mice [38,39], high-
lighting an essential role for ROCK action in HSCs. Similar 
observations have been found in various animal models, in-
cluding HFD-fed mice [40], HFD and streptozotocin (STZ)-
treated rats [41], STZ-induced diabetic rats [42], dimethylni-
trosamine-induced hepatic fibrosis rats [43], and endotoxin-
treated mice [44,45]. In animal models of CCl4-induced liver 
fibrosis, the ability of a ROCK inhibitor to reduce HSCs activa-
tion is greatly enhanced, leading to the prevention of liver fi-
brosis development [39,46-48]. Given the fact that ROCK in-
hibitors, including Y27632 and fasudil (HA1077), inhibit both 
ROCK1 and ROCK2 kinase activity [55,56], it is conceivable 
that the blockage of both isoforms may play a pivotal role in 
the protective effects of progressive liver diseases. This limita-
tion has been an issue in the field and appears to result from 
limited knowledge on the isoform specificity of ROCK inhibi-
tor. In this respect, an orally bioavailable ROCK2 inhibitor 
(ANG4201), which is >200 fold selective for ROCK2 versus 
ROCK1, has recently been developed by Angion Biomedica 
Corp. (San Francisco, CA, USA) [57]. Consistent with the 
aforementioned findings, the treatment of NASH mice with 
ANG4201 for 2 months also leads to a significant improve-
ment in fibrosis, which is associated with decreased ALT/AST 
and cholesterol [57]. Equally, another ROCK2 selective inhibi-
tor (RXC007) has been found to have the antifibrotic effect 
[58]. However, these results will need to be confirmed by a 
more specific genetic approach where ROCK2 in HSCs or he-
patocytes is genetically deleted selectively, providing definitive 
knowledge as to whether ROCK2 is an indispensable regulator 
of liver diseases. Nevertheless, these data highlight compelling 
evidence that the hyper-activation of ROCK in the liver may 
contribute to the etiopathogenesis of hepatic dysfunction and 
that ROCK is a potential therapeutic target for obesity-in-
duced fatty liver diseases such as NAFLD.
THE IMPACT OF HEPATIC ROCK1 ON 
OBESITY AND INSULIN SENSITIVITY
Earlier studies demonstrated that aberrant ROCK1 expression 
and/or activity are associated with numerous metabolic syn-
drome-related disorders, including cardiovascular disease, in-
sulin resistance, obesity, and T2DM and its complications [59-
63]. These works have never explored ROCK expression and/
or activity in the liver of altered metabolic states such as obesi-
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Table 1. Rho-kinase inhibition improves liver diseases
Animal models with liver diseases Treatments Major findings Reference
Fibrosis induced by CDAA in rats Y-27632 (1 mg/kg) was treated for 12 
weeks
Improvement of hepatic fibrosis and steatosis
Decreased ALT and HA levels
Reduced hepatic TNFα expression
[35]
Steatosis induced by choline-deficient 
diet for 6 weeks in rats and the liver 
was subjected to IR injury
Vitamin A-coupled liposomes carrying 
Y-27632 for targeted HSCs was  
administered before ischemia  
induction
Improved the survival rate after IR injury, the 
liver blood flow, and the portal perfusion  
pressure
Decreased AST levels 
[37]
Steatosis induced by choline-deficient 
diet for 6 weeks and the liver was s 
ubjected to IR injury in rats
Fasudil (10 mg/kg) was administered  
for 30 minutes before ischemia  
induction
Attenuation of HSCs activation
Improvement of IR injury
Decreased AST and ALT levels
Reduced ET-1 serum levels
[36]
Fibrosis induced by CCl4 treatment for 
12 weeks in rats
Y-27635 (30 mg/kg) was treated for  
6 weeks
Prevented the development of liver fibrosis
Decreased αSMA and TGFβ1-positive cell 
Decreased total collagen 
Increased survival rate after hepatectomy
[46,50]
CCl4-induced acute liver injury in mice Y-27632 (1.5 mg/kg) was injected at 24 
and 48 hours after CCl4 injection
Reduction of local activation of HSCs
Decreased αSMA
[47]
CCl4-induced acute liver injury in mice Single injection of HA-1077 (10 mg/kg) Reduced hepatic apoptosis
Decreased ALT levels
[51]
Fibrosis induced by CCl4 treatment for  
7 weeks in mice
Y27632 conjugate (45 mg/kg/day) that 
is taken up in activated HSCs for  
2 weeks
Inhibited activation of HSCs
Decreased ALT and AST level
Reduced liver fibrosis
[39]
Cirrhosis induced by CCl4-intoxication 
and BDL in rats
Y-27635 coupled with mannose-6- 
phosphate targeting HSCs activation
Decreased the portal pressure 
Decreased the hepatic-portal resistance
No extrahepatic effects
[38]
Cirrhosis induced by BDL or CCl4 in 
rats
Y27632 coupled with human serum  
albumin substituted with PDGFRβ-
recognizing peptides (Y27pPBHSA)
Lower portal pressure, hepatic vascular  
resistance without effect on systemic vascular 
resistance
Reduced intrahepatic resistance by decreased 
moesin and MLC
[48]
Mouse model of NAFLD induced by 
HFD
RKI-1447 (2 and 8 mg/kg) was treated 
for 3 weeks 
Decreased ALT and AST levels




Diabetic rats made by a combination of 
HFD and streptozotocin
Fasudil (10 mg/kg) was treated for  
14 weeks
Amelioration of liver fibrosis
Inhibited TGFβ1/CTGF pathway and αSMA  
expression 
[41]
Streptozotocin-induced type 1 diabetic 
rats 
Fasudil (2 mg/kg b.i.d., 10 mg/kg b.i.d., 
H-Fas group) was treated for 8 weeks
Suppression of inflammation and accumulation 
of the extracellular matrix
Downregulated TGFβ1 and MMP9/TIMP-1
Decreased NF-κB activation
[42]
Rat model of DMN-induced fibrosis Y27632 (30 mg/kg) was orally  
administered for 4 weeks
Decrease liver fibrosis
Reduced hepatic collagen and hydroxyproline
Decreased hepatic αSMA expression
[43]
(Continued to the next page)
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ty. Our study focused on investigating whether the expression 
or activity of ROCK1 in the liver changes in metabolic-linked 
diseases. In rodents, a marked increase in ROCK1 activity or 
expression is observed in the liver and adipose tissue of insu-
lin-resistant, obese, or T2DM animal models [49]. In contrast, 
a significant decrease in ROCK1 activity is detected in the hy-
pothalamus of these animals [63], suggesting site-specific reg-
ulation of ROCK1 in metabolically active organs. In individu-
als with fatty liver disease, ROCK1 expression greatly in-
creased in the liver and strongly correlated with risk factors 
clustering with fatty liver diseases or liver damage [49]. These 
data demonstrate that ROCK1 has a vital role in the pathogen-
esis of obesity-linked metabolic diseases, including NAFLD.
Given the fact that obesity is a major risk factor for develop-
ing NAFLD and drives hepatic ROCK1 expression [1,49], our 
laboratory has undertaken studies to establish the physiologi-
cal function of ROCK1 in the liver, using animal models with 
genetic modifications of hepatic ROCK1. Mice lacking hepatic 
ROCK1 are resistant to the development of obesity during 
high-fat feeding, primarily due to increased energy expendi-
ture. Hepatic ROCK1 deletion also significantly improves glu-
cose tolerance and insulin sensitivity in mice on high-fat or 
Table 1. Continued
Animal models with liver diseases Treatments Major findings Reference
Endotoxin-induced mice made by a 
combination of LPS and D-galactos-
amine
Fasudil (40 mg/kg) or Y-27632  
(10 mg/kg) by a single injection
Decreased ALT and AST levels
Decreased hepatic apoptosis
Attenuated LPS-induced liver injury
Reduced LPS-induced leukocyte adhesion
Decreased hepatic TNFα and CXC chemokines 
expression
[45]
LPS-induced acute liver injury in mice Y-27632 (10 mg/kg) was injected prior 
to LPS injection
Attenuated LPS-induced liver injury
Reduced the LPS-induced hepatic inflammatory 
response and oxidative stress 
Protective effects on hepatic mitochondrial 
function
[44]
Obstructive cholestasis induced by BDL 
in mice (hepatocellular damage)
Y-27632 (1 and 10 mg/kg) was injected 
prior to BDL
Decreased serum AST and ALT levels 




Rats underwent intrahepatic tumor  
implantation followed by orthotopic 
liver transplantation 
Y-27632 (10 mg/kg) for 28 days Suppression of cancer cell migration 
Suppression of tumor recurrence 
Increased survival rate
[53]
Mice lacking hepatic ROCK1 HFD for 16 weeks Prevented HFD-induced fatty liver
Decreased hepatic TG and cholesterol in serum 
and liver
Decreased de novo lipogenesis
[49]
Mice overexpressing a constitutively  
active mutant of ROCK1 in the liver
HFD for 12 weeks Promoted HFD-induced fatty liver
Increased serum TG and cholesterol levels
Increased hepatic TG
[49]
Leptin-deficient mice (ob/ob) mice  
lacking hepatic ROCK1
No treatment Prevented the development of fatty liver
Decreased hepatic TG and cholesterol levels
[49]
CDAA, choline-deficient/L-amino acid-defined; ALT, alanine aminotransferase; HA, hyaluronic acid; TNFα, tumor necrosis factor alpha; IR, 
ischemia-reperfusion; HSC, hepatic stellate cell; AST, aspartate aminotransferase; ET-1, endothelin-1; CCl4, carbon tetrachloride; αSMA, 
α-smooth muscle actin; TGFβ, transforming growth factor-β; BDL, bile duct ligation; PDGFRβ, platelet-derived growth factor receptor β; MLC, 
myosin light chain; NAFLD, nonalcoholic fatty liver disease; HFD, high-fat diet; CTGF, connective tissue growth factor; b.i.d., twice a day; 
MMP9, matrix metallopeptidase 9; TIMP-1, tissue inhibitors of metalloproteinases-1; NF-κB, Nuclear factor kappa B; DMN, dimethylnitrosa-
mine; LPS, lipopolysaccharide; ROCK1, Rho-associated coiled-coil-containing kinase; TG, triglyceride. 
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regular chow diets [49]. Support for this comes from a phar-
macological study showing that 6 weeks of treatment of a 
ROCK inhibitor ameliorates diet-induced obesity and glucose 
intolerance as well as energy expenditure in mice [64]. Similar-
ly, it was reported that 4 weeks of treatment with a ROCK in-
hibitor decreased body weight and improved glucose tolerance 
in obese Zucker animals [65]. However, it should be noted that 
long-term ROCK inhibition by a chemical inhibitor reduces 
body weight in insulin-resistant obese animals, which could 
possibly be secondary to insulin-sensitizing effects [64,65]. In 
keeping with these observations, our study further demon-
strates that high-fat feeding greatly promotes obesity and insu-
lin resistance in transgenic mice expressing a constitutively ac-
tive form of hepatic ROCK1 compared with control mice. The 
importance of hepatic ROCK1 action on glucose metabolism 
is further underscored by the finding that leptin-deficient ob/
ob mice lacking hepatic ROCK1 display improved insulin sen-
sitivity compared with control ob/ob mice [49]. Collectively, 
these data demonstrate that hepatic ROCK1 is necessary and 
sufficient for regulating normal body-weight homeostasis and 
glucose metabolism, establishing a key role of hepatic ROCK1 
in fuel metabolism. 
CONTROL OF DE NOVO LIPOGENESIS BY 
ROCK1 
Biochemistry and physiology of hepatic de novo lipogenesis
When an organism ingests an amount of food that exceeds its 
immediate energy needs, the excess nutrients are directed into 
the formation of storage products that can be later mobilized 
for energy generation when food is less available. Triglyceride 
represents an energy-dense and physiologically benign storage 
product and is the principal sink for the disposal of excess nu-
trient carbons. The biosynthesis of triglyceride can be consid-
ered a two-stage process: first, the formation of long-chain fat-
ty acyl CoA (LCFA-CoA) by a process known as DNL whose 
pathway is summarized in Fig. 1, and second, the sequential 
esterification of glycerol-3-phosphate by three LCFA-CoA to 
form triacylglycerol. DNL is usually the rate-limiting step for 
the synthesis of triglyceride from non-lipid precursors [66]. 
Therefore, expression and activity of the enzymes that consti-
tute the DNL pathway, coupled with the availability of precur-
sor substrates, determine the rate of hepatic triglyceride syn-
thesis [67]. DNL occurs in the cytosol and relies on the genera-
tion of cytosolic acetyl coenzyme A (acetyl-CoA) and nicotin-
amide adenine dinucleotide phosphate (NADPH). With the 
exception of a few substrates, such as the short-chain fatty acid 
acetate which can be converted to acetyl-CoA in the cytosol 
via acyl-coenzyme A synthetase short-chain family member 2 
(ACSS2) [68], almost all other nutrients are catabolized to mi-
tochondrial acetyl-CoA, which is then transferred to the cyto-
sol via the citrate shuttle. 
The pentose phosphate pathway (PPP) is the primary source 
of NADPH generation. Recent studies indicate that oxidative 
pentose pathway flux is highly coupled to that of DNL, at least 
during high-sugar feeding [69]. The generation of two NADPH 
equivalents via the PPP requires oxidation of one carbohydrate 
carbon to CO2, therefore synthesis of one equivalent of palmi-
toyl-CoA involves the oxidation of 1.17 equivalents of glucose-
6-P for the generation of NADPH alone. In part, because of its 
strong dependence on PPP activity, DNL is more responsive to 
the availability of carbohydrates compared to other nutrients. 
DNL activity is highly modulated by insulin through positive- 
and negative-feedback loops which are conditional on carbo-
hydrate availability and feeding state [70,71] and stimulated by 
sugar-sensing factors such as carbohydrate-responsive ele-
ment-binding protein (ChREBP) [72]. Thus, diets high in sim-
ple sugars such as glucose and fructose promote high hepatic 
DNL rates [73,74]. In addition to contributing directly to the 
hepatic lipid burden, DNL also attenuates hepatic fatty acid 
oxidation by generating malonyl-CoA, a potent inhibitor of 
long-chain fatty acid transported into the mitochondria via the 
carnitine shuttle. Normally, DNL is acutely suppressed follow-
ing intake of high fat/low carbohydrate diets. However, the de-
velopment of insulin resistance can result in maintaining DNL 
activity in this setting in part because of the increased avail-
ability of hepatic glucose-6-phosphate resulting from chronic 
hyperglycemia and/or uncontrolled hepatic gluconeogenesis. 
This is associated with increased ChREBP activity that upregu-
lates DNL independently of any impairments of hepatic insu-
lin signaling [75]. 
Measurement of hepatic DNL with deuterated water (2H2O)
Tracers that directly measure DNL provide estimates of frac-
tional synthetic rates (i.e., the percent contribution of DNL to 
the total triglyceride pool over a defined interval). These esti-
mates are derived from the precursor enrichment analysis, 
measured either directly or inferred from mass isotopomer 
distribution analysis (MIDA) of the product [76]. Although 
earlier studies of DNL were performed with infused [1-13C]- or 
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[1-14C] acetate, there has been a widespread shift to the use of 
2H2O, in large part because it is less costly than the acetate trac-
er and can be administered orally over an unlimited period of 
time. This latter aspect is important for the study of DNL con-
tributions to lipid pools because of their relatively slow turn-
over rates, particularly for humans. In addition, 2H2O can be 
administered to humans on an outpatient basis under “real 
life” conditions [77] or to animals without disrupting their 
normal feeding routines [78].
As shown in Fig. 1, the hydrogens of the fatty acid product of 
DNL can be traced to four specific sources: (1) body water; (2) 
the methyl hydrogens of the first acetyl-CoA molecule that 
binds to fatty acyl-CoA synthase; (3) malonyl-CoA; and (4) 
NADPH. The PPP NADPH hydrogens are in turn derived 
from hydrogens 1 and 3 of glucose-6-phosphate. When 2H2O 
is administered, the 2H rapidly mixes with the hydrogens of 
body water and is directly incorporated into the nascent fatty 
acid chain during the second hydrogenation step. In addition, 
the 2H present in body water can be incorporated into acetyl-
CoA and malonyl-CoA precursors via specific exchange pro-
cesses that occur during the formation of these metabolites. 
The NADPH hydrogens become enriched in part through ex-
change as well as by acquisition of 2H from glucose-6-P that 
was itself enriched from body water 2H via metabolic exchange 
processes associated with gluconeogenesis and Cori cycle ac-








































































































-2H +Acetyl CoA, -2H
CO2
Fig. 1. Schematic of de novo lipogenesis. Entry points for the main nutrient precursors are shown in gray and the sources of hy-
drogens of the fatty acyl coenzyme A (acyl-CoA) product are represented by different colors: ‘H+’ hydrogens derived from body 
water, black ‘H’ for the methyl hydrogens of the initial acetyl-CoA that binds to acyl-CoA synthase, red ‘H’ for the hydrogens de-
rived from nicotinamide adenine dinucleotide phosphate (NADPH) via the pentose phosphate pathway (PPP), and ‘H’ for the 
hydrogens derived from malonyl-CoA. Also represented is the acyl-CoA synthase complex (ACoAS) following the initial acetyl-
CoA and malonyl-CoA additions. Intracellular acetyl-CoA is represented as distinct mitochondrial (Acetyl-CoAMITO) and cyto-
solic (acetyl-CoACYTO) pools. CoASH, free acetyl CoA; SCoA, CoA moiety; SCFA, short chain fatty acids; OAA, oxaloacetate; CIT, 
citrate; AoCS, Co moiety.
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enriched with 2H with the level of enrichment of a particular 
hydrogen relying on that of the body water precursor and the 
extent to which the exchange processes are complete. Al-
though early studies suggested that 2H enrichment of newly-
synthesized fatty acids was only ~50% to 70% of the theoretical 
value, thereby requiring a correction factor for determining 
DNL rates [79], a more recent analysis suggests that under 
some conditions, 2H/1H exchanges approach 100% [69]. Fatty 
acids that undergo elongation also incorporate 2H by the same 
exchange mechanisms, but only into the elongated front por-
tion. Positional analysis of fatty acid enrichment by 2H nuclear 
magnetic resonance (NMR) allows elongation and DNL rates 
to be resolved [80] and for transfer of hydrogen from glucose 
via NADPH to be followed [69].
DNL measurements in animal models and humans
The deuterated water method has been widely applied to study 
the involvement of DNL in NAFLD pathogenesis in both hu-
mans and animal models. The main constraint of this mea-
surement in humans is that direct sampling of liver triglyceride 
via needle biopsy is typically not performed per se because of 
the unacceptable risk/benefit. As a less invasive alternative, tri-
glycerides from circulating very low-density lipoprotein 
(VLDL) are sampled, with the assumption that these derived 
from the hepatic triglyceride pool and therefore report the 
same tracer enrichment levels as hepatic triglyceride [81]. 
Conversion of fractional synthetic rates to absolute DNL rates 
requires an independent measurement of triglyceride turnover. 
In the liver, this is complicated by the appearance of fatty acids 
from sources other than DNL, such as from chylomicron rem-
nants and circulating non-esterified fatty acids, and a disposal 
of fatty acids by several processes other than VLDL export, 
such as mitochondrial and peroxisomal oxidation. Finally, due 
to an extensive interchange of fatty acids between adipose tis-
sues—particularly visceral adipose tissue—and the liver, a por-
tion of hepatic fatty acid and VLDL labeling may in fact have 
originated from adipocyte DNL activity [77]. For humans, the 
liver is considered the principal site of DNL synthesis; hence, 
adipocyte contributions to hepatic fatty acid labeling may be 
minor. However, for many animals including rodents and pigs, 
adipocyte lipogenesis activity contributes substantially more to 
whole body DNL rates and could therefore have a significant 
influence on hepatic lipid labeling and activity attributed to 
hepatic DNL [82,83]. Because altered DNL is highly implicated 
in the pathogenesis of NAFLD [84,85], this pathway activity 
has become a focus both toward enhancing our understanding 
of NAFLD pathogenesis and as a putative pharmacological 
target for NAFLD treatment. Table 2 provides an overview of 
selected hepatic DNL studies in human subjects with NAFLD. 
In summary, hepatic DNL contributes about 5% to 10% of he-
patic triglyceride appearance in healthy post-absorptive hu-
mans, whereas this rate is significantly elevated to 15% to 25% 
for patients with NAFLD [11,81,84,86-88]. Elevated DNL ac-
tivity is tightly associated with increased hepatic lipid levels. 
Decreases in hepatic steatosis resulting from either dietary in-
tervention (typically, a reduction in caloric intake), and phar-
macological inhibition of fatty acids synthase, are associated 
with decreases in fractional DNL rates.
Role of ROCK1 in hepatic DNL activity
Our research efforts first sought to identify a central role of 
ROCK1 in the liver mediating DNL [49]. In obese mice where 
hepatic steatosis was induced by high-fat feeding, liver-specific 
deletion of ROCK1 expression resulted in an amelioration of 
hepatic triglyceride levels [49]. We explored the physiologic 
mechanisms by which ROCK1 regulates hepatic lipid accumu-
lation by assessing DNL activity, fatty acid uptake and oxida-
tion, and hepatic VLDL release. A marked reduction in frac-
tional DNL rates determined by 2H NMR of deuterated water 
2H2O in liver-specific ROCK1-deficient mice fed a HFD was 
observed. Because these studies were performed with body-
weight matching ROCK1-deficient mice, the possible con-
founding effects of adiposity can be excluded. In relation to 
DNL measurement, differences in whole body triglyceride 
pools could modify hepatic fatty acid 2H-enrichment indepen-
dently of changes in absolute hepatic DNL rates. To demon-
strate that this effect could not be attributed to some uncharac-
terized physiological aspect of liver-specific ROCK1-deficient 
mice beside adiposity, we further studied liver-specific 
ROCK1-deficient mice fed a normal chow diet that had a simi-
lar body weight to control mice. We found that DNL rates sig-
nificantly reduced for this group of mice. However, deleting 
hepatic ROCK1 had no effects on hepatocyte fatty acid uptake 
or oxidation, and hepatic VLDL export rates. This suggests the 
decrease in hepatic lipid accumulation caused by ROCK1 defi-
ciency is solely explained by significant reductions in fractional 
DNL rates. In conjunction with DNL activity, we also investi-
gated whether decreased hepatic lipid accumulation by 
ROCK1 deletion is due to changes in gene expression of key 
enzymes involved in glucose and lipid metabolism. Consistent 
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Table 2. Selected studies of de novo lipogenesis in patients with NAFLD 
Study outline Tracer method for DNL assay Major findings Reference
DNL rates were measured in lean 
healthy subjects and in overweight 
patients with suspected NAFLD 
based on transaminase levels and 
hepatic ultrasound tests.
2H2O given over 20 hours and  
enrichment of palmitate within 
TG-rich lipoprotein measured  
after a breakfast meal.
This was among the first published study of DNL in 
NAFLD subjects using the 2H2O tracer. The  
contribution of DNL to the appearance rate of  
plasma TG was ~3-fold higher for the NAFLD  
subjects compared to the healthy controls.
[86]
Comparison of DNL contributions 
to liver TG appearance in obese 
subjects with low or with high liver 
fat but matched for other  
metabolic factors 
2H2O given over 11 days and  
enrichment of palmitate within 
TG-rich lipoprotein measured.
Subjects with high liver fat levels had a DNL  
contribution to liver fat appearance that was twice 
that of subjects with low liver TG levels.
[84]
Determine the sources of fatty acids 
contributing to hepatic TG and in 
secreted lipoprotein of NAFLD  
patients during both fed and fasted 
states
[1-13C]acetate infused over 4 days. 
Hepatic TG directly sampled by 
liver biopsy and plasma  
lipoprotein TG also sampled.
Analysis of plasma lipoprotein TG yielded similar flux 
estimates to those of liver TG. DNL accounted for 
about one-quarter of liver and plasma lipoprotein 
TG synthesis. DNL was active during both fed and 
fasted states. 
[81]
Determine the effect of age-induced 
skeletal muscle insulin resistance on 
postprandial hepatic lipid kinetics 
by studying elderly subjects and 
young subjects matched for body 
composition and physical activity
2H2O given over 2 days and  
enrichment of palmitate within 
VLDL measured.
Hepatic DNL rates were two-fold higher in the elderly 
cohort. Hepatic lipid levels were three-fold higher in 
the elderly cohort. These were associated with  
increased fasting plasma glucose levels and increased 
muscle insulin resistance as seen by impaired muscle 
glycogen synthesis rates.
[87]
Determine the effects of a fatty acid 
synthase inhibitor (FT-4101) on 
hepatic DNL rates in NAFLD  
patients
2H2O given over 14 days and  
enrichment of VLDL-palmitate 
measured during a period of 
fructose ingestion.
12 Weeks of FT-4101 administration significantly  
decreased fractional DNL rates over placebo in a 
dose-dependent manner. This was accompanied by a 
significant decrease in liver TG levels. 
[88]
Compare DNL rates in lean subjects 
without NAFLD, obese subjects 
without NAFLD and obese subjects 
with NAFLD before and after 
placement on a weight-loss diet
2H2O given over 3−5 weeks and  
enrichment of palmitate within 
TG-rich lipoprotein measured.
DNL rates were highest in obese-NAFLD subjects and 
were directly correlated with plasma insulin and  
glucose concentrations. Moderate weight loss resulted 
in significant decreases in both DNL rates and liver 
TG levels that was linked to significant decreases in 
plasma glucose and insulin levels.
[11]
NAFLD, nonalcoholic fatty liver disease; DNL, de novo lipogenesis; TG, triglyceride; VLDL, very low-density lipoprotein.
with the results of DNL rates, deficiency of ROCK1 in the liver 
caused a significant decrease in gene expressions of key en-
zymes involved in lipogenesis but not gluconeogenesis, glycol-
ysis, fatty acid oxidation and uptake. Importantly, these effects 
were also observed in ob/ob mice lacking hepatic ROCK1 in-
dependent of changes in body weight. Together, these data 
suggest the major mechanism by which deletion of ROCK1 in 
the liver prevents hepatic steatosis could be through decreased 
DNL, mediated by the reduced expression of lipogenic en-
zymes. Thus, our studies identify hepatic ROCK1 as a princi-
pal regulator of fat metabolism and further implicate that inhi-
bition of hepatic ROCK1 could be a novel therapeutic target 
for the treatment of NAFLD.
ROCK1 MEDIATES ENDOCANNABINOID-
INDUCED LIPOGENESIS
The endocannabinoid system is comprised of the cannabinoid 
receptor 1 (CB1 receptor) and 2 (CB2 receptor), their endoge-
nous lipidic ligands (endocannabinoids), and the enzymes in-
volved in endocannabinoid synthesis and degradation [89]. 
The CB1 receptor is mainly found in the brain and is responsi-
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ble for the psychotropic and behavioral effects after the use of 
cannabinoids. The CB2 receptor is expressed in metabolically 
active peripheral organs such as the liver, adipose tissue, and 
pancreas [90,91] and functions as a key modulator of innate 
immunity and fuel metabolism, amongst other roles [91,92]. 
In particular, during the progression of liver diseases, CB1 re-
ceptor expression is induced in hepatocytes, hepatic myofibro-
blasts, and endothelial cells of the liver, whereas CB2 receptor 
expression is up-regulated in Kupffer cells [89,93]. In this re-
gard, a significant increase in CB1 and CB2 receptor expres-
sion in the liver of humans with NAFLD was observed [94,95], 
suggesting that dysregulation of the endocannabinoid system 
may contribute to the pathogenesis of liver diseases.
Two arachidonic acid-containing endocannabinoids, arachi-
donoylethanolamide (anandamide [AEA]) and 2-arachidon-
oylglycerol (2-AG), are identified as ligands for the CB1 and 
CB2 receptors [96-99]. AEA and 2-AG play important roles in 
regulating glucose and lipid metabolism. These functions en-
tail lipogenic enzymes activation and fat accumulation in the 
liver [100], modulation of insulin secretion in islets [101,102], 
stimulation of lipoprotein lipase activity in adipose tissue 
[103], and decreases in insulin-stimulated glucose uptake and 
fatty acid oxidation in muscle [103,104]. All these features are 
key hallmarks involved in the pathogenesis of metabolic syn-
drome. 
Antagonism and agonism of the CB1 and CB2 receptors 
have been extensively studied in the experimental settings of 
liver diseases and diet-induced obesity [105]. Numerous stud-
ies have been performed with an inverse agonist/antagonist 
rimonabant for the CB1 receptor. These investigations have 
obtained consistent outcomes on the metabolic benefits of he-
patic lipid metabolism in various liver diseases models [106-
111]. Recent studies have also demonstrated that inverse ago-
nist/antagonists targeting the peripheral CB1 receptor amelio-
rate metabolic parameters in animal models of obesity and dia-
betes [111-115]. For example, treating diet-induced obese mice 
with a pyrazole-based inverse agonist of the CB1 receptor 
(RTI1092769) that has minimal brain exposure decreased he-
patic triglyceride contents and improved hepatic steatosis 
[111]. Another peripherally-restricted inverse agonist for the 
CB1 receptor, JD5037, is found to have a therapeutic potential 
in metabolic disorders of the peripheral tissues such as the liver 
[113,114]. In fact, JD5037 attenuated HSCs activation of liver 
fibrosis by inhibiting β-arrestin1/Akt signaling in humans and 
rodents [115]. These pharmacological observations have been 
supported by the evidence from a genetic model of liver-spe-
cific CB1 receptor knockout mice [100]. Mice lacking the CB1 
receptor in the liver have significantly less hepatic steatosis, hy-
perglycemia, and dyslipidemia during over-nutrition [100], 
highlighting an important role for the CB1 receptor in regulat-
ing normal hepatic metabolism. Selective studies of the endo-
cannabinoid system in the context of liver diseases are showed 
in Table 3 [106-111,116-124]. 
In proof-of-concept studies, we made the novel observation 
that endocannabinoids, AEA and 2-AG, strongly increased the 
catalytic activity of ROCK1 in the liver and HepG2 cells [49] 
and DNL rate in hepatocytes. Concurrently, gene expression of 
key lipogenic enzymes, including fatty acid synthase (FAS), 
stearoyl-CoA desaturase-1 (SCD1), acetyl-CoA carboxylase 
(ACC), and sterol regulatory element-binding protein 1c 
(SREBP1c) also markedly increased in response to 2-AG in the 
liver. However, the lack of endocannabinoids’ response on lip-
ogenic gene expression was noted when hepatic ROCK1 was 
absent, suggesting that ROCK1 activation is necessary to regu-
late the endocannabinoid-mediated lipogenic program. We 
further hypothesize that ROCK1-dependent lipogenesis is me-
diated through inhibition of AMP-activated protein kinase 
(AMPK), as evidenced from our data showing that 2-AG sup-
pressed the activity of hepatic AMPK in control mice but not 
in liver-specific ROCK1-deficient mice. In addition, ROCK1 
deletion stimulated AMPK activity but ROCK1 activation sup-
pressed AMPK activity in the liver, further highlighting a neg-
ative regulation of ROCK1 for AMPK. Therefore, our work has 
provided mechanistic insight into the fundamental function of 
ROCK1 in regulating the endocannabinoid-dependent lipo-
genic program.
THE REGULATORY MECHANISMS 
UNDERLYING ROCK1-MEDIATED 
LIPOGENESIS
Experimental evidence has demonstrated that AMPK plays a 
pivotal role in regulating glucose and fatty acid metabolism. 
AMPK, a highly conserved serine/threonine protein kinase, 
was viewed as a cellular sensor that responds to depletion in 
cellular energy reserves by switching off anabolic pathways and 
enhancing catabolic processes [125]. Activation of the AMPK 
and its downstream signaling pathways was found to suppress 
hepatic lipid synthesis [126], increase muscle fatty acid oxida-
tion [127], and enhance insulin action [128]. In particular, ac-
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Table 3. Blockade of endocannabinoid signaling ameliorates liver diseases
Animal model of metabolic  
dysfunction
Treatments Major findings Reference
Obese Zucker fa/fa rats Rimonabant (30 mg/kg/day) was  
orally administered for 8 weeks
Decreased plasma ALT, GGT, and ALP levels
Decreased hepatic TNFα levels
Reduced plasma TG and cholesterol levels
Improved hepatic steatosis
[106]
OLETF rats Rimonabant (10 mg/kg/day) was  
orally administered for 6 weeks
Decreased serum ALT and AST levels
Decreased hepatic TG levels
Improved hepatic steatosis
[107]
C56BL/6J mice fed a HFD for 20 
weeks
Rimonabant (10 mg/kg) was orally  
administered from 18th to 20th  
week 
Decreased serum AST and ALT levels




Sprague-Dawley rats fed a  
choline-deficient diet for  
12 weeks
Rimonabant (10 mg/kg) orally  
administered from 10th week to 12th 
week
Decreased serum AST and ALT levels
Decreased hepatic malondialdehyde levels 
Increased hepatic glutathione peroxidase activity
Reduced hepatic TGFβ immunoreactive area
[109]
Male C57BL/6 mice fed a HFD for 
20 weeks
Rimonabant (10 mg/kg) was orally  
administered from 18th week to 20th 
week
Decreased serum AST and ALT levels
Decreased adipokines levels (leptin, visfatin, IL-6, 
IFNγ levels in adipose tissue)
Reduced hepatic-6, IFNγ levels
Improved hepatic steatosis
[110]
C57Bl/6J male mice fed a HFD 
underwent hypoxia exposure for 
10 weeks
CB1 receptor agonist (WIN55212-2,  
1 mg/kg) was treated for 4 weeks
Hypoxia-induced improvement in hepatic steatosis 
was abolished by CB1 receptor agonist
Increased hepatic CB1 and SREBP1 expression
[116]
Male Sprague-Dawley and WKY 
rats injected with LPS/D- 
galactosamine (acute liver injury 
model)
CB2 agonist (JWH-133, 2.5 mg/kg) or 
CB1 antagonist (AM6545, 10 mg/kg) 
was acutely injected
CB1 antagonist or CB2 agonist had no effect on 
LPS/D-galactosamine-induced liver injury
[117]
NAFLD was induced by a high-fat 
cholesterol diet for 6 weeks
Cannabis extracts (5 mg/kg) were  
administrated orally every 3 days for 
6 weeks
No change in hepatic lipid accumulation
CBD-rich extracts increased hepatic iNOS and 
TNFα expression
THC-rich extracts decreased liver enzymes
[118]
Mice lacking CHOP fed a HFD for 
14 weeks
CB1R blocker (JD5037, 3 mg/kg) was 
administered for 7 days
Failed to reverse DIO-induced reduction of sOB-R 
levels and hepatic steatosis
[119]
Liver fibrosis induced by  
thioacetamide (200 mg/kg) 
treatment for 6 weeks in rats
AM1241 (CB2 receptor activator,  
3 and 6 mg/kg) was injected for  
3 weeks
Suppressed hepatic TNFα, IL-1b, and IL-6 levels
Decreased hepatic TLR4, TGFβ1, αSMA, and  
miR-155 gene expression
Inhibited the development of fibrosis
[120]
APOE∗3-Leiden.CETP transgenic 
mice fed Western-type diet for 
20 weeks
Rimonabant (20 mg/kg/day) for  
4 weeks 
Decreased plasma TG and non-HDL levels
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tivated AMPK decreases the hepatic gene expression of the lip-
ogenic transcription factor SREBP1c and its downstream tar-
gets ACC, SCD1, and FAS [126]. Although ROCK1 has not 
been suspected to be involved in AMPK signaling, our work 
reveals that AMPK acts as a downstream regulator of ROCK1 
in the context of hepatic DNL [49]. In fact, ROCK1 negatively 
regulates AMPK activity, as demonstrated by the evidence that 
AMPK activity increased due to ROCK1 deletion but de-
creased by ROCK1 activation in the liver. Correspondingly, re-
ciprocal changes in hepatic lipogenesis are seen (i.e., de-
crteased or enhanced fatty acid synthesis caused by AMPK ac-
tivation or suppression due to ROCK1 deletion or hyperactiva-
tion, respectively). Pharmacological modulations of AMPK 
activity in hepatocytes are enabled to regulate gene expression 
of key lipogenic enzymes despite the metabolic conditions 
where ROCK1 is either absent or activated, further confirming 
that ROCK1 is an upstream component of AMPK signaling. 
Thus, our data suggest the hepatic ROCK1 → AMPK signaling 
cascade is a crucial determinant of hepatic lipid synthesis (Fig. 
2) [49]. This novel pathway appears to be functional in re-
sponse to an insulin sensitizer metformin [129], which further 
implicates clinical significance and relevance of ROCK1 signal-
ing. Of note, our recent work further identified Gα12 or Gαs as 
an upstream component of ROCK1 → AMPK signaling dur-
ing melanocortin stimulation in the hypothalamus [130]. Thus, 
it is important to know that Gα12 or Gαs plays a role in the de-
velopment of NAFLD in the context of ROCK1 action (Fig. 2). 
The liver X receptors (LXRs), LXRα and LXRβ, play a pivot-
al role in regulating lipid and glucose metabolism in insulin-
target tissues by controlling its downstream targets’ gene ex-
pression [131,132]. Insulin induces LXRα in hepatocytes, re-
sulting in an increased expression of key enzymes in lipogene-
sis, including SREBP1c, the master regulator of hepatic lipo-
genesis, and its several downstream genes such as FAS and 
SCD1 [133-135]. A central role for LXRs in the regulation of 
lipogenesis is further established by the study showing that de-
leting LXRs from ob/ob mice reduces hepatic triglyceride 
amounts and lipogenic gene expression [136]. Conversely, 
treating mice with synthetic LXR agonists promotes triglycer-
ide synthesis in the liver by inducing lipogenic gene expression 
[137,138], thereby leading to hypertriglyceridemia, a risk fac-
tor for developing insulin resistance and obesity [133]. The fact 
Animal model of metabolic  
dysfunction
Treatments Major findings Reference
Obese mice fed on a HFD RTI1092769 (inverse agonist/ 
antagonist of CB1)
Decreased hepatic TG contents
Decreased plasma AST and ALT levels
Improved hepatic steatosis
[111]
C57BL/6J and fat-1 transgenic 
mice fed a LFD for 10 weeks +10 
weeks of a HFD
Fatty acids SAF oil or LIN oil were 
supplemented to a LFD for 10 weeks, 
prior to HFD exposure
Decreased hepatic AEA and 2-AG contents in 
LIN-treated mice
Improved glucose tolerance and insulin tolerance 
in LIN-treated mice
[122]
Global CB1 receptor knockout 
mice
SR161716A (10 mg/kg) was injected 
before and after CCl4
Reduced fibrosis associated with chronic liver  
injury
Decreased hepatic TGFβ1 expression
[123]
Global CB1 receptor knockout 
mice
No treatment Decreased hepatic TG levels
Reduced hepatic PLIN2 expression
Suppressed lipogenesis
[124]
ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; ALP, alkaline phosphatase; TNFα, tumor necrosis factor alpha; TG, triglycer-
ide; OLETF, Otsuka Long-Evans Tokushima Fatty; AST, aspartate aminotransferase; HFD, high-fat diet; TGFβ, transforming growth factor-β; 
IL-6, interleukin 6; IFNγ, interferon gamma; CB1, cannabinoid receptor type 1; SREBP1, sterol regulatory element-binding protein 1; WKY, 
Wistar Kyoto; LPS, lipopolysaccharide; CB2, cannabinoid receptor type 2; NAFLD, nonalcoholic fatty liver disease; CBD, cannabidiol; iNOS, in-
ducible nitric oxide synthase; THC, tetrahydrocannabinol; CHOP, C/EBP homologous protein; CB1R, cannabinoid receptor type 1 receptor; 
DIO, diet-induced obesity; sOb-R, soluble leptin receptor; IL-1b, interleukin 1b; TLR4, toll like receptor 4; αSMA, α-smooth muscle actin; HDL, 
high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; VLDL, very low-density lipoprotein; LFD, low-fat diet; SAF, safflower 
oil; LIN, linseed oil; AEA, arachidonoylethanolamide; 2-AG, 2-arachidonoylglycerol; CCl4, carbon tetrachloride; PLIN2, perilipin 2.
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that deficiency of hepatic ROCK1 selectively suppresses gene 
expression of lipogenic key enzymes in the liver [49] allowed 
this research to raise the possibility that LXRα is involved in 
ROCK1 action in the context of lipogenesis. Interestingly, co-
immunoprecipitation assay indicates that ROCK1 physically 
binds to LXRα in the liver and possibly could phosphorylate 
LXRα serine residues in vitro (not shown). Whether LXRα is a 
critical determinant for the metabolic regulation of ROCK1-
mediated DNL by controlling its target gene expression is an 
intriguing question that future studies should address. These 
investigations will establish the biological significance of 
ROCK1-dependent LXRα action in hepatic metabolism and 
provide a novel mechanism for the ROCK1 → LRXα signaling 
axis that is linked to lipogenesis (Fig. 2). 
SUMMARY
Significant progress in comprehending the critical signaling 
pathways that regulate normal glucose and lipid homeostasis 
has been made in the field. In particular, much attention has 
focused on hepatic fatty acid metabolism in the context of obe-
sity-related NAFLD. Growing evidence from pharmacological 
and genetic studies demonstrated that ROCK1 plays an essen-
tial role in the homeostatic regulation of DNL in the liver and 
its activation is the key defect that underlies the etiology of 
obesity-linked NAFLD. In addition, the ROCK1 → AMPK 
signaling cascade is required to mediate hepatic DNL pro-
voked by endocannabinoid generated from HSCs. Thus, the 
































Fig. 2. Role of Rho-associated coiled-coil-containing kinase (ROCK1) in the development of nonalcoholic fatty liver disease 
(NAFLD). High-fat feeding increases endocannabinoids 2-arachidonoylglycerol and anandamide levels produced from hepatic 
stellate cells of the liver. Endocannabinoids stimulate ROCK1 activity via cannabinoid receptor type 1 (CB1), which inhibits 
AMP-activated protein kinase (AMPK) activity. Suppressed AMPK activity then drives the sterol regulatory element-binding 
protein 1c (SREBP1c)-mediated lipogenic program, leading to a rise of lipid accumulation. NAFLD ultimately develops with the 
progression of obesity. On the other hand, it is hypothesized that activated ROCK1 binds to liver X receptor (LXRα) and may 
prompt the lipogenic pathway through SREBP1c. As an early event of ROCK1 signaling, CB1-mediated Gα12 (or Gαs) activation 
could be an initial step for ROCK1-dependent de novo lipogenesis. GTP, guanosine triphosphate; FAS, fatty acid synthase; SCD1, 
stearoyl-CoA desaturase-1; ACC, acetyl-CoA carboxylase.
Sousa-Lima I, et al.
668 Diabetes Metab J 2021;45:655-674 https://e-dmj.org
tabolism provides new insight into the etiopathogenesis of 
NAFLD and may lead to new treatment approaches for obesi-
ty-related metabolic disorders such as NAFLD.
Outstanding questions are as follows:
•  What are the specific roles of ROCK1 or ROCK2 in HSCs 
in the development of liver diseases?
•  What are the functions of ROCK1 or ROCK2 in Kupper 
cells?
•  Is ROCK1 involved in the regulation of LXRα-mediated 
lipogenic programs?
•  What are the key downstream pathways of ROCK1 → 
AMPK signaling?
•  What is the physiological role of the ROCK1 → AMPK 
signaling pathways in other metabolic organs?
•  Does Gα12 or Gαs act as an upstream signal of ROCK1 in 
the liver?
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